Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER3 | P43115 | 1/20 | 0.39 |
| ▸ | PER2 | O15055 | 3/20 | 0.35 |
| ▸ | CRY2 | Q49AN0 | 2/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
| ▸ | HTR5A | P47898 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2762729 | 0.83 | P4HB (0.44) | MAPTMEN1KMT2AKDM4ELMNA | |
| SCHEMBL13036165 | 0.79 | SLC6A4 (0.39) | PTGER3DRD2DRD4 | |
| SCHEMBL13036168 | 0.79 | SLC6A4 (0.39) | PTGER3DRD2DRD4 | |
| SCHEMBL13036172 | 0.79 | SLC6A4 (0.39) | PTGER3DRD2DRD4 | |
| SCHEMBL13036162 | 0.79 | SLC6A4 (0.39) | PTGER3DRD2DRD4 | |
| SCHEMBL13084823 | 0.79 | PTGER3 (0.34) | PTGER3 | |
| SCHEMBL13036390 | 0.77 | PTGER3 (0.33) | PTGER3HSD11B1KDM4E | |
| SCHEMBL13036391 | 0.77 | PTGER3 (0.33) | PTGER3HSD11B1KDM4E | |
| SCHEMBL13074142 | 0.76 | PER2 (0.39) | PTGER3PER2CRY2HSD11B1MAPT | |
| SCHEMBL2762999 | 0.73 | CHRM2 (0.47) | MEN1KMT2ALMNAADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825264-B2 | Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them | SANOFI-AVENTIS (FR) | 2010-11-02 | — | — | US | disclosed |
| EP-1899320-B1 | SUBSTITUTED PYRR0LIDIN-2-0NES , PIPERIDIN-2-0NES AND ISOTHIAZOLIDINE-1, 1-DIOXIDES, THEIR USE AS KV1 .5 POTASSIUM CHANNEL BLOCKERS AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | SANOFI AVENTIS (FR) | 2010-10-20 | — | — | EP | disclosed |
| US-20080188520-A1 | Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them | SANOFI-AVENTIS (FR) | 2008-08-07 | — | — | US | disclosed |
| CN-101203508-A | Substituted pyrr0lidin-2-0nes , piperidin-2-0nes and isothiazolidine-1, 1-dioxides, their use as kvl .5 potassium channel blockers and pharmaceutical preparations comprising them | SANOFI AVENTIS DEUTSCHLAND (FR) | 2008-06-18 | — | — | CN | disclosed |
| EP-1899320-A1 | SUBSTITUTED PYRR0LIDIN-2-0NES , PIPERIDIN-2-0NES AND ISOTHIAZOLIDINE-1, 1-DIOXIDES, THEIR USE AS KVl .5 POTASSIUM CHANNEL BLOCKERS AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | Sanofi-Aventis (FR) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006136305-A1 | SUBSTITUTED PYRR0LIDIN-2-0NES , PIPERIDIN-2-0NES AND ISOTHIAZOLIDINE-1, 1-DIOXIDES, THEIR USE AS KVl .5 POTASSIUM CHANNEL BLOCKERS AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | SANOFI-AVENTIS (DE) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188520-A1 | Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them | KCNH1, MLLT3, CYP1A2 | PTGER3 400/4885PER2 954/4885CRY2 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.